is jardiance a glp 1 inhibitor TrimRX AHA: Lilly, Boehringer's Jardiance cuts

She got supervised

Findings: RCTSURMOUNT-2 trial - Tirzepatide vs Placebo for Weight Loss in Diabetes, Lancet (2023) [PubMed abstract] Design: Randomized, placebo-controlled trial (N=938 | length = 72 weeks) in overweight diabetics (mean BMI 36 | mean A1C 8.02%) Treatment: Tirzepatide 10 mg once weekly vs Tirzepatide 15 mg once weekly vs Placebo Primary outcome: Coprimary endpoints were the percent change in body weight from baseline and body weight reduction of 5% or higher Results: Primary outcome (% reduction in weight): Tirzepatide 10 mg - 12.8%, Tirzepatide 15 mg - 14.7%, Placebo - 3.2% (p 35 - 68.9% Randomized treatment groups Group 1 (374 patients): Tirzepatide titrated to the maximum tolerated dose of 10 mg or 15 mg once weekly Group 2 (376 patients): Semaglutide titrated to the maximum tolerated dose of 1.7 mg or 2.4 mg once weekly Tirzepatide was initiated at a dose of 2.5 mg once weekly, and the dose was increased by 2.5 mg every 4 weeks until a maximum tolerated dose of 10 mg or 15 mg was reached

A 2023 observational study noted that patients receiving both therapies experienced greater reductions in body mass index compared to single-agent therapy, though the sample size was modest and long-term safety data remain incomplete

Filmmaker John Landis, who directed two music videos for Jackson, said when Jackson showed him his bleached chest, Landis told him the doctor who had done it was a criminal

Hydration emerges as a linchpin in the journey of weight loss, particularly for individuals embarking on GLP-1 therapy